BeyondSpring presents preclinical data on Plinabulin ADC combinations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
April 22, 2026 7:01 AM EDTNew Preclinical Results at AACR 2026 Show Plinabulin Dramatically Improves Complete Response Rates and Survival When Combined with Leading ADC Drugs With or Without Immunotherapy
Plinabulins GEF-H1 Agonist Mechanism Drives Synergistic Antitumor Activity And CIN Mitigation Across TOP1-ADC ± PD-1/PD-L1 Inhibitor Regimens in Preclinical Models
FLORHAM PARK, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:... More
